PDGFRB and neoplasm: JNJ-10198409 (JNJ) which competes for the ATP binding site in the PDGFR tyrosine kinase domain and has potent antiproliferative activity [8] that is able to inhibit PDGFR downstream signaling in tumor tissues in vivo [9].